No evidence for the role of somatic mutations and promoter hypermethylation of FH gene in the tumorigenesis of nonsyndromic uterine leiomyomas

[1]  N. Shaik,et al.  Enhanced transcription of estrogen receptor α and mitochondrial cytochrome b genes in uterine leiomyomas , 2011, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[2]  G. Shadel,et al.  Revisiting the TCA cycle: signaling to tumor formation. , 2011, Trends in molecular medicine.

[3]  N. Shaik,et al.  Detection of somatic mutations and germline polymorphisms in mitochondrial DNA of uterine fibroids patients. , 2011, Genetic testing and molecular biomarkers.

[4]  K. Kavanagh,et al.  Structural basis of fumarate hydratase deficiency , 2011, Journal of Inherited Metabolic Disease.

[5]  Q. Hasan,et al.  Regulation of IGF2 transcript and protein expression by altered methylation in breast cancer , 2011, Journal of Cancer Research and Clinical Oncology.

[6]  P. Mandich,et al.  A Novel Missense Mutation in Fumarate Hydratase in an Italian Patient with a Diffuse Variant of Cutaneous Leiomyomatosis (Reed’s Syndrome) , 2010, Dermatology.

[7]  Predrag Radivojac,et al.  Automated inference of molecular mechanisms of disease from amino acid substitutions , 2009, Bioinform..

[8]  P. Park,et al.  Identifying the molecular signature of the interstitial deletion 7q subgroup of uterine leiomyomata using a paired analysis , 2009, Genes, chromosomes & cancer.

[9]  A. Dobrovic,et al.  No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. , 2009 .

[10]  N. Shaik,et al.  Estrogen Receptor-α gene (T/C) Pvu II Polymorphism in Endometriosis and Uterine Fibroids , 2009, Disease markers.

[11]  Jean-Pierre Bayley,et al.  The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency , 2008, BMC Medical Genetics.

[12]  C. Morton,et al.  Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. , 2007, Human molecular genetics.

[13]  W. Parker.  Etiology, symptomatology, and diagnosis of uterine myomas. , 2007, Fertility and sterility.

[14]  I. Hassinen,et al.  Inhibition of Hypoxia-inducible Factor (HIF) Hydroxylases by Citric Acid Cycle Intermediates , 2007, Journal of Biological Chemistry.

[15]  R. Houlston,et al.  No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. , 2006, Cancer letters.

[16]  W. Linehan,et al.  Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer , 2006, Journal of Medical Genetics.

[17]  J. Moult,et al.  Identification and analysis of deleterious human SNPs. , 2006, Journal of molecular biology.

[18]  Yuen-Li Chung,et al.  HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. , 2005, Cancer cell.

[19]  J. R. Chaudhuri,et al.  MTHFR C677T gene mutation as a risk factor for arterial stroke: a hospital based study , 2005, European journal of neurology.

[20]  R. Poulsom,et al.  Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome , 2005, The Journal of pathology.

[21]  B. Glaser,et al.  Germline fumarate hydratase mutations in families with multiple cutaneous and uterine leiomyomata. , 2003, The Journal of investigative dermatology.

[22]  D. Dixon,et al.  Etiology and pathogenesis of uterine leiomyomas: a review. , 2003, Environmental health perspectives.

[23]  N P Burrows,et al.  Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. , 2003, Human molecular genetics.

[24]  I. Tomlinson,et al.  The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase , 2003, Annals of medicine.

[25]  P. Bork,et al.  Human non-synonymous SNPs: server and survey. , 2002, Nucleic acids research.

[26]  B. Delahunt,et al.  Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. , 2002, Cancer research.

[27]  R. Houlston,et al.  Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas , 2002, British Journal of Cancer.

[28]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[29]  L. Aaltonen,et al.  Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. , 2001, The American journal of pathology.

[30]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[31]  M. Perola,et al.  Heritability and risk factors of uterine fibroids--the Finnish Twin Cohort study. , 2000, Maturitas.

[32]  V. Ramesh,et al.  Molecular analysis and prenatal diagnosis of human fumarase deficiency. , 1998, Molecular genetics and metabolism.

[33]  C. Gellera,et al.  Fatal mitochondrial encephalopathy caused by fumarase deficiency: A molecular-genetic study , 1994 .

[34]  A. Munnich,et al.  Mutation of the fumarase gene in two siblings with progressive encephalopathy and fumarase deficiency. , 1994, The Journal of clinical investigation.

[35]  L. Aaltonen,et al.  Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. , 2004, The American journal of pathology.

[36]  M. Szklo,et al.  Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. , 2001, American journal of epidemiology.